Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Merck KGaA | 1,513 |
| 2 | Merck and Co Inc | 1,183 |
| 3 | Gilead Sciences Inc | 631 |
| 4 | Bristol Myers Squibb Co | 604 |
| 5 | Pfizer Inc | 338 |
| 6 | Pharmamar SA | 305 |
| 7 | AbbVie Inc | 281 |
| 8 | Bayer AG | 216 |
| 9 | Madrigal Pharmaceuticals Inc | 151 |
| 10 | Euro Celtique SA | 124 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 11,222 |
| 2 | A61K | Medicinal preparations | 9,256 |
| 3 | C07D | Heterocyclic compounds | 6,767 |
| 4 | C07K | Peptides | 2,751 |
| 5 | C12N | Microorganisms, enzymes | 915 |
| 6 | Y02A | Climate change adaptation | 874 |
| 7 | G01N | Investigating / analysing materials | 722 |
| 8 | C07C | Acyclic and carbocyclic compounds | 665 |
| 9 | C07B | General methods of organic chemistry | 483 |
| 10 | C07F | Organometallic compounds | 463 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| APLIDINE FOR MULTIPLE MYELOMA TREATMENT | 2004 | Dana Farber Cancer Institute Inc | 13 |
| Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | 2008 | Pharmamar SA | 12 |
| Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | 2010 | Pharmamar SA | 8 |
| TREATMENT OF CANCERS BY APLIDINE IN CONJUNCTION WITH A MYOPROTECTOR | 2003 | Pharmamar SA | 4 |
| SYNTHETIC METHODS FOR APLIDINE AND NEW ANTITUMORAL DERIVATIVES, METHODS OF MAKING AND USING THEM | 2003 | Pharmamar SA | 4 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 12 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | José Jimeno | PharmaMar (Spain) | 22 |
| 2 | Alejandro Losada | PharmaMar (Spain) | 10 |
| 3 | Pablo Avilés | PharmaMar (Spain) | 10 |
| 4 | Alberto Múñoz | Universidad Autónoma de Madrid | 9 |
| 5 | Maurizio D’Incalci | Mario Negri Institute for Pharmacological Research | 9 |
| 6 | Luis López Lázaro | PharmaMar (Spain) | 8 |
| 7 | José A. López-Martín | PharmaMar (Spain) | 8 |
| 8 | Pablo Guisado‐Vasco | Universidad Europea de Madrid | 7 |
| 9 | Glynn Faircloth | PharmaMar (Spain) | 7 |
| 10 | María José Muñoz-Alonso | PharmaMar (Spain) | 6 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A | 2021 | 367 | SARS-CoV-2 and COVID-19 Research |
| Cytoskeleton-mediated Death Receptor and Ligand Concentration in Lipid Rafts Forms Apoptosis-promoting Clusters in Cancer Chemotherapy | 2005 | 183 | Protein Kinase Regulation and GTPase Signaling |
| AplidinTM Induces Apoptosis in Human Cancer Cells via Glutathione Depletion and Sustained Activation of the Epidermal Growth Factor Receptor, Src, JNK, and p38 MAPK | 2002 | 156 | Synthesis and biological activity |
| Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4 | 2003 | 145 | Angiogenesis and VEGF in Cancer |
| Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates | 1996 | 140 | Chemical Synthesis and Analysis |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of plitidepsin?
Which companies hold the most patents related to plitidepsin?
What are the main research topics associated with plitidepsin publications?
Which author has the highest publication count on plitidepsin research?
What patent classifications are most common in the plitidepsin patent landscape?